Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 911-915

  Rörsch, Florian ^a   Wobst, Ivonne ^a   Zettl, Heiko ^a   Schubert Zsilavecz, Manfred ^a   Grösch, Sabine ^a   Geisslinger, Gerd ^a   Schneider, Gisbert ^a   Proschak, Ewgenij ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMPUTER SIMULATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MICROSOMES;

EID: 77249100287     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9012505     Document Type: Article

References (28)

1. Cryer, B.; Kimmey, M. B. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998, 105, 20S-30S.
2. Tegeder, I.; Geisslinger, G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn-Schmiedeberg's Arch. Pharmacol. 2006, 373, 1-17.
3. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-1102.
4. Simon, L. S.; Weaver, A. L.; Graham, D. Y.; Kivitz, A. J.; Lipsky, P. E.; Hubbard, R. C.; Isakson, P. C.; Verburg, K. M.; Yu, S. S.; Zhao, W. W.; Geis, G. S. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 1999, 282, 1921-1928.
5. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA, J. Am. Med. Assoc. 2000, 284, 1247-1255.
6. Jegerschöld, C.; Pawelzik, S. C.; Purhonen, P.; Bhakat, P.; Gheorghe, K. R.; Gyobu, N.; Mitsuoka, K.; Morgenstern, R.; Jakobsson, P. J.; Hebert, H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11110-11115.
7. Jakobsson, P.; Thoren, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7220-7225.
8. Samuelsson, B.; Morgenstern, R.; Jakobsson, P. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007, 59, 207-224.
9. Murakami, M; Naraba, H; Tanioka, T; Semmyo, N; Nakatani, Y; Kojima, F; Ikeda, T; Fueki, M; Ueno, A; Oh, S; Kudo, I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 2000, 275, 32783-32792.
10. Friesen, R. W.; Mancini, J. A. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J. Med. Chem. 2008, 51, 4059-4067.
11. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E(2) synthase-1 and 5-lipoxygenase. J. Med. Chem. 2008, 51, 8068-8076.
12. Xu, D.; Rowland, S. E.; Clark, P.; Giroux, A.; Cote, B.; Guiral, S.; Salem, M.; Ducharme, Y.; Friesen, R. W.; Methot, N.; Mancini, J.; Audoly, L.; Riendeau, D. MF63 {2-(6-chloro-1H-phenanthro-[9,10-d]imidazol-2-yl) isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J. Pharmacol. Exp. Ther. 2008, 326, 754-763.
13. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. "Scaffold- hopping" by topological pharmacophore search: a contribution to virtual screening. Angew. Chem., Int. Ed. 1998, 38, 2894-2896.
14. Schneider, G.; Wrede, P. Artificial neural networks for computer-based molecular design. Prog. Biophys. Mol. Biol. 1998, 70, 175-222.
15. Noeske, T.; Sasse, B. C.; Stark, H.; Parsons, C. G.; Weil, T.; Schneider, G. Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists. ChemMedChem 2006, 1, 1066-1068.
16. Côté, B.; Boulet, L.; Brideau, C.; Claveau, D.; Ethier, D.; Frenette, R.; Gagnon, M.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Massé, F.; Méthot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6816-6820.
17. Riendeau, D.; Aspiotis, R.; Ethier, D.; Gareau, Y.; Grimm, E. L.; Guay, J.; Guiral, S.; Juteau, H.; Mancini, J. A.;Méthot, N.; Rubin, J.; Friesen, R. W. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett. 2005, 15, 3352-3355.
18. Proschak, E.; Zettl, H.; Tanrikulu, Y.; Weisel, M.; Kriegl, J. M.; Rau, O.; Schubert-Zsilavecz, M.; Schneider, G. From molecular shape to potent bioactive agents I: bioisosteric replacement of molecular fragments. ChemMedChem 2009, 4, 41-44.
19. Proschak, E.; Rupp, M.; Derksen, S.; Schneider, G. Shapelets: possibilities and limitations of shape-based virtual screening. J. Comput. Chem. 2008, 29, 108-114.
20. Tanrikulu, Y.; Nietert, M.; Scheffer, U.; Proschak, E.; Grabowski, K.; Schneider, P.; Weidlich, M.; Karas, M.; Göbel, M.; Schneider, G. Scaffold hopping by "fuzzy" pharmacophores and its application to RNA targets. ChemBioChem 2007, 8, 1932-1936.
21. Bradford, M. M.Arapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein - dye binding. Anal. Biochem. 1976, 72, 248-254.
22. Thorén, S.; Jakobsson, P. J. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur. J. Biochem. 2000, 267, 6428-6434.
23. Schmidt, R.; Coste, O.; Geisslinger, G. LC-MS/MS-analysis of prostaglandin E2 and D2 in microdialysis samples of rats. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2005, 826, 188-197.
24. Wobst, I.; Schiffmann, S.; Birod, K.; Maier, T. J.; Schmidt, R.; Angioni, C.; Geisslinger, G.; Grösch, S. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem. Pharmacol. 2008, 76, 62-69.
25. Båge, T.; Modéer, T.; Kawakami, T.; Quezada, H. C.; Yucel-Lindberg, T. Regulation of prostaglandin E synthases: effects of siRNA-mediated inhibition of microsomal prostaglandin E synthase-1. Biochim. Biophys. Acta 2007, 1773, 1589-1598.
26. Schneider, P.; Tanrikulu, Y.; Schneider, G. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem. 2009, 16, 258-266.
27. Noeske, T.; Trifanova, D.; Kauss, V.; Renner, S.; Parsons, C. G.; Schneider, G.; Weil, T. Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1. Bioorg. Med. Chem. 2009, 17, 5708-5715.
28. Renner, S.; Hechenberger, M.; Noeske, T.; Böcker, A.; Jatzke, C.; Schmuker, M.; Parsons, C. G.; Weil, T.; Schneider, G. Searching for drug scaffolds with 3D pharmacophores and neural network ensembles. Angew. Chem., Int. Ed. 2007, 46, 5336-5339.